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AbstractCitrobacter amalonaticus is a bacterium that has rarely been reported as a human pathogen. Here we report four cases of C. amalonaticus
infections occurring in patients hospitalized in Marseille, France, and review all cases described in the published literature.
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ﬁrst studied and described in 1971 after being isolated fromvarious
human samples from hospitalized patients, especially faeces [1].
Since then this bacterial species has been isolated from the envi-
ronment [2,3] as well as sporadically isolated from humans, mainly
in faecal, urine, wound and respiratory samples [1,4–9]. Recently
our syndromic clinical laboratory-based surveillance system, called
BALYSES (the BActerial real-time LaboratorY-based SurveillancE
System) [10], detected two consecutive C. amalonaticus kidney
infections in two renal transplant recipients hospitalized in the
same nephrology unit in Conception Hospital, Marseille, France.
An additional two cases of C. amalonaticus infection were then
detected over the following fewweeks at other university hospitals
in Marseille. We report here all cases from the literature to date.Case ReportsCase 1
A 75-year-old woman with chronic renal failure due to mem-
branoproliferative glomerulonephritis who had received aNew Microbes and New Infections © 2016 The Authors. Published by El
This is an open access artitransplant in December 2010 was admitted to the nephrology
unit of Conception Hospital for a regular check of her renal
transplant. Since her transplantation the patient had developed
membranoproliferative glomerulonephritis in the kidney trans-
plant, urinary tract infections (UTIs) and diabetes as a result of
immunosuppressive therapy. At admission in December 2014
analysis of a urine sample revealed leukocyturia (29.8 elements/
mm3) and bacteriuria (104/mL C. amalonaticus, identiﬁed by
matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectrometry (MALDI-TOF; Bruker Daltonics, Leipzig, Ger-
many)). Antimicrobial susceptibility testing revealed that the
isolate was resistant to amoxicillin and susceptible to third-
generation cephalosporins, carbapenem, cotrimoxazole, cipro-
ﬂoxacin and amoxicillin/clavulanate. The patient was treated
with amoxicillin/clavulanate during 7 days and was considered
cured.
Case 2
A 61-year-old man who had received a renal transplant in
November 2014 visited the nephrology unit at Conception
Hospital for his weekly checkup in December 2014. In the urine
samples collected, leukocyturia was 25.2 elements/mm3, and
bacteriuria was 104/mL with C. amalonaticus, which was iden-
tiﬁed by MALDI-TOF. In this case C. amalonaticus was resistant
to amoxicillin, ticarcillin and cotrimoxazole and susceptible to
amoxicillin/clavulanate, ticarcillin/clavulanate, third-generation
cephalosporins, carbapenems, nitrofurantoin, gentamicin and
ciproﬂoxacin. The patient was treated a ﬁrst time in December
with ciproﬂoxacin during 7 days; antibiotic therapy was rec-
ommended only during urologic surgery. He underwent
treatment a second time from 11 March 2015 to 3 April 2015.New Microbe and New Infect 2016; 11: 1–5
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FIG. 1. Annual evolution of number of patients with Citrobacter amalonaticus infections at our hospital from January 2002 to December 2014.
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A 4-year-old child with Leigh syndrome, which is a mitochon-
drial cytopathy due to a heterozygote mutation on the SURF1
gene, was admitted to the intensive care unit at Timone Hos-
pital for cardiogenic shock due to Epstein-Barr virus infection
on 16 February 2015. On 6 April 2015 a urine sample was
collected; analysis revealed that leukocyturia was 35 elements/
mm3, hematuria 8 elements/mm3 and bacteriuria 104/mL. The
bacterium C. amalonaticus, identiﬁed by MALDI-TOF, was
resistant to amoxicillin, amoxicillin/clavulanate, ticarcillin and
ticarcillin/clavulanate and susceptible to carbapenems, third-
generation cephalosporins, carbapenems, nitrofurantoin, cip-
roﬂoxacin and cotrimoxazole. The patient was treated with
cotrimoxazole and was cured after 7 days of treatment.
Case 4
A 27-day-old newborn girl was brought into the paediatric unit
in North Hospital on 4 March 2015 for rhinitis and fever
(temperature 38.3°C). A urine sample was collected; analysis11, 31%
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FIG. 2. Main features of 36 patients with Citrobacter amalonaticus infections. (A
kinds of samples from which bacterium was isolated.
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107/mL C. amalonaticus. The strain was susceptible to amoxi-
cillin/clavulanate, ticarcillin/clavulanate, ciproﬂoxacin, cotri-
moxazole, nitrofurantoin, carbapenems and third-generation
cephalosporins but resistant to amoxicillin and ticarcillin. The
patient was symptomatically treated with paracetamol for fever;
no antibiotic treatment was provided for asymptomatic urinary
colonization.
Epidemiologic features
Because the two initial cases were reported in the nephrology
unit in renal transplant recipients, we looked at our updated 13-
year historical database [11] and retrospectively found that 36
patients had experienced C. amalonaticus infections before 2015
(Fig. 1). Most of the infections occurred in male subjects (21
male and 15 female patients), were hospital-acquired infections
(22 infections, 62%) and were UTIs (29/36, 80%) (Fig. 2). We
also identiﬁed a peak in the number of infected patients in 2012:
a total of 12 patients were infected that year (Fig. 1). When we29, 80%
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TABLE 1. Characteristics of patients with Citrobacter amalonaticus infections reported in our studies and elsewherea
Case, no. of
patient
(country)
Age
(years)/sex
Infection
type Underlying condition
Sampling
date
Identiﬁcation
method
Antibiotic
therapy Issue Reference
1, 1 (China) 47/F Peritonitis IgA nephropathy, renal graft,
intermittent peritoneal dialysis
NA Biochemical
tests and16S
rRNA
CAZ AK Cure [9]
2, 1 (Italy) 63/F Wound infection ABMT, AML, intracranial haemorrhages NA Vitek 2 system TG Cure [4]
3, 1 (Taiwan) 75/M Bacteraemia Ampulla vater cancer NA Phoenix automated
system
CMZ Cure [6]
4, 1 (Italy) NA NA Renal allograft 10 months earlier NA API 20E NA NA [12]
5, 1 (Thailand) 53/M Enteric fever Fever, water diarrhoea, headache, travel to
Asia
NA Biochemical tests CRO SXT Cure [8]
6, 5 (USA) 2 patients NA Urinary tract abnormality, diabetes,
malignancy
NA Biochemical tests NA NA [7]
3 patients NA Diabetes mellitus NA NA NA
1, 1 (France) 77/F Urinary tract
infection
Renal graft, chronic nephropathy, diabetes 02/03/15 MALDI-TOF AMC Cure Our study
2, 1 (France) 61/M Urinary tract
infection
Renal graft, lymphatic cyst of graft, ureter
stenosis, diabetes
10/12/14
04/03/15
MALDI-TOF CIP Cure Our study
3, 1 (France) 4/M Urinary tract
infection
Leigh syndrome 04/02/15 MALDI-TOF SXT Cure Our study
4, 1 (France) 0/F Asymptomatic
urinary
colonization
Fever, rhinitis 04/03/15 MALDI-TOF No Cure Our study
ABMT, allogenic bone marrow transplantation; AMC, amoxicillin/clavulanate; AMT, acute myelogenous leukaemia; CAZ, ceftazidime; CIP, ciproﬂoxacin; CMZ, cefmetazole; CRO,
ceftriaxone; Ig, immunoglobulin; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-ﬂight mass spectrometry; NA data not available; SXT, cotrimoxazole; TG,
tigecycline.
Case = number of cases previously described in the literature; no of patient = number of patients infected in the case report.
aOnly studies reporting fully described infections with well-identiﬁed C. amalonaticus are included.
NMNI Garcia et al. C. amalonaticus in UTIs 3compared the global number of patients experiencing
C. amalonaticus UTIs before 2012 and since 2012 to the number
of patients experiencing Escherichia coli UTIs over the same two
time periods, based on our updated 13-year historical database
[11], we observed that there were statistically more UTIs due to
C. amalonaticus after the 2012 peak than before (11 in 25 789
patient–bacteria pairs from 2002 to 2011 vs. 18 of 13 502 pa-
tient–bacteria pairs from 2012 to 2014; p 0.003). Moreover, we
observed that the majority of the strains were collected from
young children (11 patients, 31% of all infected patients). When
we compared the proportion of patients experiencing
C. amalonaticus infection who were younger than 11 years old to
that of E. coli infection, based on our historical database [11], we
noted that the proportion of patients under 11 years infected by
C. amalonaticus was statistically higher than that of E. coli (11 of
6361 patient–bacteria pairs vs. 25 of 43 169 patient–bacteria
pairs; p 0.003). Furthermore, we statistically identiﬁed more
patients infected with C. amalonaticus after the introduction of
MALDI-TOF technology for routine bacteria identiﬁcation in
our laboratory [11] in 2009 than before (nine of 82 436 pa-
tient–bacteria pairs from 2002 to 2008 vs. 27 of 115 922 pa-
tient–bacteria pairs from 2009 to 2014; p 0.04) (Fig. 1).DiscussionC. amalonaticus has only rarely been isolated in humans (Table 1).
In 2009, a Chinese woman who had received a kidney
transplant contracted peritonitis due to C. amalonaticus. In
another study, a 63-year-old woman who had undergone boneNew Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on beh
This is an open access artimarrow transplantation developed wound infection caused by
C. amalonaticus. Another case concerned a 75-year-old man with
pancreatic cancer who contracted a biliary tract infection and
bacteraemia due to C. amalonaticus. In Italy, it was recovered
from a urine sample in one patient who had received a renal
graft 10 months earlier. In the United States, between 1972 and
1978, at the Seattle Veterans Administration Medical Center,
C. amalonaticus was identiﬁed in urine and ﬂuid samples from ﬁve
patients. Among these patients, two had UTIs. In Thailand, a man
contracted enteric fever, and C. amalonaticus was incriminated.
In our study, we identiﬁed four cases of C. amalonaticus
infection by MALDI-TOF. The four spectra were then included
in a dendrogram built with Bruker MALDI Biotyper 3.0 software
(Fig. 3). Among all cases reported, including ours, we observed
ﬁve patients who had undergone kidney transplantation or who
had a urinary tract abnormality (case 6) [7]. Also, we observed
that patients were mainly immunocompromised, including a
patient with a renal graft [9,12], a newborn patient (case 4) and
patients with leukaemia and pancreatic cancer (cases 2 and 3)
[4,6]. Taken together, our observations and those in previously
published reports (Table 1) lead us to think that this bacterium
is an opportunistic pathogen, especially in patients with urinary
tract failure. The fact that C. amalonaticus infection was rarely
reported in the past may be explained by the fact that this
bacterium is difﬁcult to identify (Table 1). Thus, conventional
methods such as the API system and RapID onE may underes-
timate their prevalence by misidentifying the strains [7,13–16].
The fact we statistically identiﬁed more C. amalonaticus in-
fections after we instituted the routine use of the MALDI-TOF
may have resulted in an improvement in the identiﬁcation of thisalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 11, 1–5
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
FIG. 3. Main-spectrum dendrogram of four Citrobacter amalonaticus isolates built from protein spectra.
4 New Microbes and New Infections, Volume 11 Number C, May 2016 NMNIbacterial species. However, we found a statistically higher
prevalence of the number of UTIs due to this bacterium even
after routine use of MALDI-TOF (after 2012), suggesting that it
is likely that this bacteria could be an emerging pathogen
responsible for UTIs in immunocompromised patients.AcknowledgementsSupported in part by the Centre National de la Recherche
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